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Abstract
The pathogenesis of irritable bowel syndrome (IBS) has been intensively researched,
and despite a long journey for unraveling all the structures and the pathways involved,
it still remains partially obscure. Inflammation was the first to be hypothesized as a
potential pathway for the pathogenesis of IBS. It remains a keystone in the complex
machinery of the pathogenesis that is currently considered multifactorial. Elucidating
the pathogenesis of IBS is crucial for a targeted therapy of the disease. In this chapter,
we review information regarding gut inflammation in IBS, underlining some of the
newest data or the cornerstones. Additionally, our aim was also to review treatment
currently available and future perspectives regarding anti‐inflammatory treatments for
IBS.  Newer  techniques  allow  detection  and  research  of  mediators  involved  in
inflammation, as well as their potential role to be targeted by pharmacological agents.
Recent data supports not only further research of the newer agents that are currently
being  developed  but  also  some  of  the  available  ones  that  do  not  have  sufficient
evidence. Emerging therapies that target inflammation are under evaluation, in trials.
A multidrug or a multidisciplinary approach needs to be considered in some cases that
fail to respond to current treatment.
Keywords: anti‐inflammatory, inflammation, irritable bowel syndrome, IBS treatment,
postinfectious
1. Introduction
Despite the intensive research on irritable bowel syndrome (IBS) is being conducted, the
pathogenesis still remains partially obscure. Since the description of this syndrome, many
researchers have questioned the cause of IBS, which is currently being considered as
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multifactorial [1–3] with increasing evidence that support the concept [4, 5], since there are
multiple mechanisms that could trigger the clinical complaints.
Not just one structure or system is involved in the occurrence of IBS, and there is a complex
network already described and currently referred to as brain‐gut axis [6–9] with multiple
directions and ways to communicate or interrelate between these structures and paths [10] that
are reflected also in the heterogeneity of the subtypes of IBS.
Although IBS is a functional gastrointestinal disorder [11] with no structural or biochemical
abnormalities, there is some evidence suggesting that in some subtypes of IBS, inflammation
might play a key role in generating a low‐grade inflammatory response and a spectrum
of symptoms that sometimes overlap with those of inflammatory bowel diseases in
remission [12, 13], leading to difficulties in establishing the diagnosis in clinical practice.
In this chapter, we will review literature data concerning inflammation and its relation to IBS
underlining some of the newest data or the key ones. Our aim was also to review treatment
currently available and future perspectives regarding anti‐inflammatory treatments for IBS.
2. Inflammation in IBS
Inflammation, defined as the answer of the immune system to various triggers, was first
described by Celsus [14], who has assigned to it the four signs: dolor (pain), rubor (redness),
tumor (swelling), calor (heat), and to which Rudolf Virchow [15] added functio laesa (functional
impairment). All the characteristics that define inflammation are induced by a complex set of
mediators [16]. In addition, the triggers that could initiate inflammatory responses are
numerous and diverse [17]. The inflammatory responses may be acute or chronic [16, 17].
Inflammation was one of the first hypothesised causes of IBS [18]. Intestinal inflammation was
proposed as a potential mechanism involved in the pathogenesis of IBS since 1960s, when Hiatt
et al. [18] described mast cells in the muscularis externa of the terminal colon and cecum.
Discovered by Paul Ehrlich, mast cells are the precursors of CD34+ hematopoietic stem cells
[19]. Due to the diversity of functions of mast cells, they have been a cornerstone in the study
of multiple conditions, being intensively researched in the last decades. Mast cells have
multiple functions [20], some of them involving the gut: neuroimmune interactions, epithelial
secretion and permeability, and visceral sensation [20, 21]. In addition, it can express receptors
for several cytokines that are involved in immunity [19] or release key mediators [22]. Nu‐
merous studies assessed the presence and/or the role of mast cells in IBS [23–25]. There are
also rigorous papers that reviewed studies investigating mast cells and/or the mast cell
mediators in IBS [26].
Other types of mediators, such as immunoglobulin (Ig) E and atopia, have been investigated
in IBS and linked to mast cells [27, 28]. Degranulation of mast cells and, subsequently, the
release of mast cell mediators can also be induced by IgE [28]. There are few data regarding
IgE levels in IBS. Vara et al. [29] showed higher levels of IgE in IBS compared with healthy
controls.
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Besides mast cells, there are data indicating that inflammatory cells are present in colonic
mucosa in IBS patients [23]. They showed on colonic biopsies multiple types of cells such as
neutrophils and T lymphocytes besides mast cells, all of which may support the role of the
immune system in the ethiopathogenesis of IBS [23, 30]. If most of the studies examined mucosa
of the rectum [31, 32], there are few studies that assessed also the deeper layers of the enteral
wall [33]. There is a complex local response when triggers are detected [16, 34].
The balance of pro‐inflammatory and anti‐inflammatory responses and the mediators that are
involved in the complex interactions have also been the subject of many studies. There is
evidence of sustained inflammation in IBS supported by numerous studies that have detected
low anti‐inflammatory cytokines in IBS patients [35] or others that found high levels of those
pro‐inflammatory ones or a misbalance of the pro‐ and anti‐inflammatory cytokine propor‐
tion [36, 37]. The complex dialogue between the structures involved in maintaining the
homeostasis includes interrelation of nervous, immune, and endocrine systems [30, 34], where
a pivotal piece is the brain that governs the humoral and neurological systems [34, 38, 39], in
a complex network with multidirectional communicating systems [10]. Not only the anatom‐
ical integrity but also the functional status of all the systems is of major importance [40].
Psychological factors can participate in this mechanism, maintaining a state of low inflamma‐
tion [41]. Inflammation in the gut might be responsible also for hyperalgesia [42] present in
some patients with IBS contributing to the maintenance of the complaints.
2.1. Postinfectious IBS
Postinfectious IBS (PI‐IBS) is a more recently coined type of IBS, initially identified as post‐
dysenteric IBS (PD‐IBS) [43]. PI‐IBS is defined as a subset of IBS in which the onset of IBS
symptoms develops after an infectious episode and was first described by Chaudhary and
Truelove [43]. This entity was confirmed by other studies [44]. The incidence of PI‐IBS varies
between 4 and 32% [45–47]. More frequently, PI‐IBS was described and studied after an
enteral infection [44, 48]. Pathogens already recognized to be involved in enteral infections
are the following:
• bacteria: Campylobacter jejuni [31], Salmonella enterica [45], Shigella [49], Escherichia coli [50–
52], Clostridium difficile [53]
• viruses: Norovirus [50, 54]
• parasites: Giardia lamblia [50, 55], Blastocystis spp. [56], Dientamoeba fragilis [57]
This subset of IBS patients offers a strong support emphasizing the importance of inflammation
as one of the main paths to IBS. Enteral pathogens may induce pathological changes [31]. Spiller
et al. [31] reported an imbalance of the enteroendocrine cells and of T lymphocytes, these two
being assessed by histopathological examination of the rectal biopsies of the PI‐IBS when
compared with controls. There can be at least three scenarios: a prolonged normal inflamma‐
tory response, an augmented pathological inflammatory response in these patients, or there
is a certain group of patients with particular characteristics that have a higher susceptibility
[44, 58–60]. Anyway, there is not yet a firm conclusion.
Inflammation as a Potential Therapeutic Target in IBS
http://dx.doi.org/10.5772/66193
27
2.2. Barrier function
The gut barrier function is important in modulating the gut inflammation [26, 61]. The barrier
has multiple roles and its integrity is essential for a normal functionality of the digestive
system [61]. An impaired barrier could facilitate the passage of inflammatory triggers that
might induce changes in the gut. An increased permeability of the barrier might expose various
structures to antigen contact [31].
2.3. Cholinergic system
There is another important piece in the complex domino of Inflammation – the so‐called
“cholinergic anti‐inflammatory pathway” [34, 62, 63]. We did not intend to review the data
regarding this system as there are multiple reviews [34] that have already analyzed the
evidence, but to find the studies that support the interrelation with inflammation in IBS. Dinan
et al. [64] investigated several cytokines, such as interleukin (IL): IL‐6, IL‐8, IL‐10, and the
growth hormone in the two arms of the study. They found that only IL‐6 and the growth
hormone in the group of IBS patients were overproduced when compared with controls after
the administration of pyridostigmine that might suggest the implication of the cholinergic
system [64].
2.4. Low‐grade inflammation
More and more data sustain the hypotheses of a low‐grade inflammation in IBS [65–67]. The
fine line between normal to a pathological inflammatory response is still difficult to set. There
is a low‐grade inflammation of the gut that has been already acknowledged and literature data
supports the putative role of the low‐grade inflammation in IBS [65–68]. Several articles
addressed this issue, some authors investigated tissue samples [23], while others assessed
blood or stool samples [69–72] in order to detect and determine the inflammation status in IBS
patients.
There are already numerous studies that assessed erythrocyte sedimentation rate, C‐reactive
protein (CRP) from blood sample, fecal calprotectin, and/or lactoferin in order to detect their
presence in IBS and/or to calculate their predictive values [71–73]. Valuable information was
provided by a meta‐analysis, although that assessed their cut‐off values in order to exclude
inflammatory bowel diseases [74].
There are limited data regarding the presence of high‐sensibility CRP [69] in IBS, but results
indicate that when compared with healthy subjects, levels of high sensibility CRP are statisti‐
cally significantly higher in IBS patients (P < 0.001) [69]. So literature data supports the presence
of low‐grade inflammation in IBS since the levels of high‐sensibility CRP, though were still
within the normal range, were higher in IBS than in controls [69].
A similar situation is for calprotectin, which is used mainly for differential diagnosis of in‐
flammatory bowel diseases [73], but there are also studies that showed increased levels of
calprotectin in IBS patients when comparing the values of those of healthy controls [72].
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In the search to quantify the levels of inflammation, many authors proposed various bio‐
markers, and others proposed multiple biomarkers such as a panel or a set of markers [75,
76].
2.5. Genes and inflammation in IBS
Genetic factors have also been suspected as being involved in the inflammation in IBS.
Regarding genes and polymorphism, there are several studies that have assessed gene
polymorphism, of which IL‐10 and α tumor necrosis factor are some of the ones that are being
intensively investigated [77–79].
As for the other studies that addressed IBS, their findings are inconsistent since some of
the studies that assessed IL‐10 genotypes in IBS patients versus controls showed high‐
producer genotype for IL‐10 had a lower frequency statistically significant in IBS than in
controls (P = 0.003) [79], and other studies did not find statistically significant difference
of IL‐10 polymorphism in IBS patients [78]. Schmulson et al. [78] assessed two
polymorphisms: IL‐10 (‐1082G/A) and α tumor necrosis factor (‐308G/A) in IBS patients
and compared them with controls. There were no statistically significant differences between
IBS and controls regarding either of the two polymorphisms.
There are also other studies besides these that assessed single nucleotide polymorphisms and
more complex studies such as genome‐wide association studies [80].
2.6. New hypotheses
There is a growing interest in applying the latest techniques used in molecular biology also
for the study of IBS, such as the study of microRNA—miRNAs [81], small interfering RNA—
siRNAs [82] or new approaches such as meta‐omics [83].
Recently, new directions have been proposed in the study of the etiopathogenesis of IBS [81,
84]. The role of stem cells has been already intensively researched [85, 86], even in inflammatory
bowel diseases [87], but these potent cells have raised interest about their role or potential use
in IBS.
Very recent data advances the hypotheses that intestinal stem cells might be involved in the
inflammatory paths discussed in IBS [84, 88]. Due to their properties, stem cells not only are
able to respond to pathogens but also may modulate the spectrum of answers by their secretory
functions [84, 89]. These stem cells might also represent therapeutic targets [84], but future
studies to identify a specific target, either structural or functional, of the stem cells are
mandatory.
The scientific community is eager to develop and improve current technologies, both for
identifying new therapeutic targets and also for new treatment.
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3. Anti‐inflammatory treatment
Treatment of IBS still represents a challenge for clinicians. Due to the marked heterogeneity
of the IBS subtypes, we will address anti‐inflammatory agents used or those with potential
use in IBS. Considering the multifactorial etiology, there are authors who propose a treat‐
ment determined by the main pathological path that led to IBS [4]. Literature data are limit‐
ed concerning pharmacological anti‐inflammatory classes studied in IBS as well as for the
number of the members of these pharmacological classes that were investigated. Since we
cannot still establish the main cause that led to IBS, an etiopathogenetic treatment is not
possible, and some are currently being developed; a main aim in the treatment of IBS still is
to alleviate the symptoms [1]. Though there are few studies that assessed anti‐inflammatory
classes or members of these classes in IBS, there is an intensive research activity into unrav‐
eling new targets and new treatments [90]. There are ongoing trials [91] and research pro‐
grams and networks [92] that bring valuable information for a deeper understanding of IBS.
4. Aminosalicylic acid agents
Since the discovery of 5‐aminosalicylic acid agents (5‐ASA) by Svartz [93] and afterward with
their active properties being described by Azad et al. [94], these agents were intensively
researched as well as used in clinical practice [95]. The 5‐ASA derivates have been used in
several inflammatory conditions such as the inflammatory bowel disorders [95]. There are
already consistent data regarding the efficacy of 5‐ASA in ulcerative colitis [95] as well as
regarding their safety. The rationale for prescribing 5‐ASA agents in IBS is represented by their
anti‐inflammatory properties and is the result of several mechanisms [96].
Article Type of article Conclusions
Min et al. [97] Letter In selected subgroups of IBS might be efficient
Törnblom et al. [98] Commentaries In selected subgroups of IBS might be efficient
Lazaraki et al. [99] Review Inconclusive regarding the use of mesalasine in IBS
Camilleri et al. [100] Review Inconclusive, though some studies show a positive
effect on pain, results were not replicated by others
Xue et al. [101] Letter Inconclusive—analyzed impact of mesalazine on gut microbiota
Hanevik et al. [102] Letter + pilot CT Inefficient
Farup et al. [103] Letter Inconclusive – authors underline that
Andrews et al. [108] did not analyze drop out patients in their study
Table 1. Articles reviewing the use of 5‐ASA in IBS.
Though there are few original studies, there are also reviews that analyze the use of 5‐ASA
in IBS (Table 1). Literature data indicate that in certain group of patients such as those with
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PI‐IBS, especially the IBS with diarrhoea (IBS‐D) subtype could benefit, at least for a certain
period of the anti‐inflammatory effects of this class (see Tables 1 and 2). Regarding the
length of treatment, dosing, and schemes of treatment, there are few data in the literature,
and there is no study to assess all of this. Future studies are required in order to configure
an a priori set of features regarding what type of IBS patient is likely to respond to 5‐ASA
treatment, as well as the regimen and dosing.
Article Type of article,
type of IBS
Dose and time of
treatment
Conclusions
Barbara et al. [104] Placebo‐controlled
trial (CT),
multicentre IBS
800 mg tid, 12 weeks Mesalazine treatment was not statistically
significant or more efficient than placebo (P =
0.870). In certain groups of patients,
it might be useful.
Lam et al. [105] CT, IBS‐D 2 g/day—2 weeks, if
tolerated 2 g bid—11 
weeks
In certain groups of selected IBS‐D patients, it
might be efficient, although there is no clear
evidence of it being useful.
Bafutto et al. [106] Pilot study, IBS‐D Various dosing—in the
fourth groups
May be useful in certain groups of patients.
Tuteja et al. [107] CT, PI‐IBS 1.6 g bid, 12 weeks No statistically significant improvement of
symptoms (P ≥ 0.11) nor QOL (P ≥ 0.16).
Andrews et al. [108] Pilot study, IBS‐D 1.5 g bid, 4 weeks Significant improvement of pain.
Bafutto et al. [109] CT, IBS‐D 800 mg tid, 30 days Significant improvement of total symptom
score, inclusive of pain.
(P < 0.0001)
Dorofeyev et al. [110] CT, IBS, all
subtypes
500 mg qid, 28 days Statistical improvement of abdominal pain
(P < 0.01) as well as some
histopathological aspects.
Hanevik et al. [102] Letter + pilot CT 800 mg bid, 6 weeks Inefficient.
Corinaldesi et al.
[111] 
CT, IBS 800 mg tid, 8 weeks Mesalazine significantly improved only
general well‐being (P = 0.038), having no
significant statistic effect regarding bloating
(P = 0.177), abdominal pain (P = 0.084), or
bowel habits.
Preobrazhenskii
[112]* 
Study 4–6 g daily, not shown Efficient.
*Articles in other languages (Russian) or full text could not be retrieved.
Table 2. Studies assessing 5‐ASA agents in IBS.
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4.1. Acetylsalicylic acid
Regarding the use of acetylsalicylic acid, we have identified just one study that assessed it in
relation to IBS, but the purpose of the study was to determine if certain anti‐inflammatory
drugs could induce constipation [113]. In fact, the study assessed that the use of some anti‐
inflammatory drugs among acetylsalicylic acid was related to constipation. [113].
4.2. Mast cell stabilizers
Mast cell stabilizers (cromoglycate and ketotifen) have been tested in IBS, but there are very
few literature data concerning this class of drugs. Also, the criteria used for diagnosing IBS
were different; therefore, there is no uniformity when comparing these studies. Subsequent
studies are mandatory in order to have the answer: which IBS patients are suited to a mast cell
stabilizer treatment and what is the dosing, or what is a suitable regimen.
4.3. Ketotifen
Klooker et al. [114] investigated ketotifen, suggesting that it can reduce visceral hypersensi‐
tivity and improve the quality of life. Though there is just one study to investigate ketotifen in
IBS patients, there has already been questions about its safety [115]. For certain other studies,
to assess this class for IBS treatment is mandatory in order to grade the levels of evidence.
Although there is just one study with positive results, we also consider encouraging these
results [33], and we strongly feel that there are more therapeutic options that have not yet been
explored.
4.4. Cromoglycate
Regarding cromoglycate, there are several studies that assessed it in IBS patients. Literature
data suggest that they could have a beneficial role in certain groups of patients, especially in
those who have also food allergies or intolerances (see Table 3). There are methodological
issues concerning these studies; so in order to reduce some of the biases, rigorous parallel
studies are needed.
Article Conclusion
Leri et al. [116] Efficient (in conjunction with dietary exclusions in IBS patients with food intolerance)
Stefanini et al. [117] Efficient (in IBS patients with food intolerance)
Grazioli et al. [118] Efficient (in pediatric IBS patients with food intolerance)
Stefanini et al. [119] Efficient (in IBS patients with food intolerance)
Lunardi et al. [120] Efficient (in IBS patients with food intolerance)
Paganelli et al. [121] Inconclusive
Antico et al. [122]* —
Stefanini et al. [123] Efficient
Tomecki et al.* [124] Inefficient
*Article in other languages than English (Polish, Italian) also could not be retrieved.
Table 3. Articles that assessed cromoglycate in IBS.
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4.5. Montelukast
There is just one report of the use of montelukast in IBS stating a positive effect [125]. Consid‐
ering the pathways that are involved in the pathogenesis of IBS, it seems reasonable that the
authors proposed and used it. The wonder is that there are so few data regarding it, though
there are data regarding IBS and allergies [29]. Montelukast might be an option for the patients
who have IBS and allergic conditions, but there is a lack of studies to address this issue.
Rigorous trials with such drugs are needed in order to conclude about their use in IBS.
4.6. Corticosteroids
Some authors even proposed corticosteroids as anti‐inflammatory agents in IBS [126]. A short
course‐3 weeks, 30 mg prednisolone/day was administered to PI‐IBS patients and compared
with placebo. There was no statistically significant difference between the number of entero‐
chromaffin cells between patients treated with prednisolone and those that received placebo
(P = 0.5). Though for the reduction of the number of T lymphocytes in the lamina propria.
Dunlop et al. [126] found a statistically significant difference that favors prednisolone, there
was no improvement regarding several symptoms of IBS.
Due to their known side effects, one study investigated the impact of using oral steroids,
showing that they do not have a higher risk for inducing IBS symptoms in adults under 40
years [127].
We conducted a search on PubMed search motor between 1–21st July 2016 using multiple
strategies as seen in Table 4. There is just one study that assessed the corticoid therapy in IBS,
though there are several authors who consider corticosteroids as a reasonable treatment option
in certain subgroups of IBS patients (Table 4).
Strategy Results Appropriate Inappropriate
“Corticosteroids, irritable bowel syndrome” 91 2 [127, 128] 89
“Corticosteroids, IBS” 64 1 [128] 63
“Prednisone, irritable bowel syndrome” 5 0 5
“Prednisolone, irritable bowel syndrome” 12 1 [126] 11
“Prednisolone, IBS” 5 1 [127] 4
“Budesonide, irritable bowel syndrome” 10 1 [128] 9
Table 4. Results retrieved by several search strategies on PubMed search motor.
4.7. Imunglobulin E antibody (Omalizumab)
There is just one study that addresses this issue [28], which presents a case of a patient that
had concurrently IBS and asthma. The patient received an IgE antibody with a major im‐
provement of IBS symptoms. These results suggest that in certain subgroups of patients with
concurrent diseases as IBS and atopic status, or extra‐intestinal symptoms, IgE antibodies
might be useful.
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5. Conclusions
Inflammation remains an important pathway involved in the pathogenesis of IBS. Despite the
high interest in the field of functional gastrointestinal disorders, till now, researchers have not
entirely discovered all the pieces of the complex puzzle that is the etiopathogenesis of IBS, or
all of the components of the pathways that finally lead to IBS.
Newer techniques allow detection and promote research of mediators that are involved in
inflammation, even in low amounts. Also, the new technologies are able to identify new
structures, as well as their potential role to be targeted by pharmacotherapeutic agents.
Results suggest that there are potential pharmacological classes, alongside with potential
therapeutic targets that deserve to be reassessed for IBS.
Recent data supports further research of the pathways and structures involved, as well as
assessment of not only the newer agents that are currently being developed but also of some
of the available ones that do not have sufficient evidence. Emerging therapies that target in‐
flammation are under evaluation, in trials. A multidrug or a multidisciplinary approach
needs to be considered in cases that fail to respond to current treatment or to a single thera‐
py, heading toward the current trend, of a personalized medicine.
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